Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc.

UNCY·NASDAQ

$7.23

+4.7%
HealthcareBiotechnology

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

At a Glance

Live Snapshot
Market Cap$155.38M
EPS-1.6700
P/E Ratio-34.52
Earnings Date08/13/2026

uncy

Shares Outstanding

Last Annual Value

158.87M

3-Year CAGR

373%

5-Year CAGR

153%

10-Year CAGR

70%

Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. Competitors Analysis of shares-outstanding

UNCY · NASDAQ
Companyshares-outstanding
CAGR 3Y
CAGR 5Y
CAGR 10Y
158.87M
301.5%167.1%N/A 
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
230.35M
-22.1%-13.9%20.7%
CBUS logo
Cibus, Inc.
NASDAQ:CBUS
457.57M
254.0%-4.6%-1.5%
279.02M
225.2%119.7%59.2%
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
10.61M
10.1%6.0%5.8%
IMA logo
ImageneBio Inc
NASDAQ:IMA
4.87M
-51.1%-33.0%N/A
69.58M
17.8%10.6%N/A
52.54M
3.0%3.1%N/A
33.38M
10.3%15.2%32.5%
38.51M
20.4%24.4%N/A
52.23M
15.3%17.0%N/A
Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. Fair Value Envelope

UNCY · NASDAQ

Our analysis suggests that UNCY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.23, this represents a potential HIDDEN relative to our calculated worth for Unicycive Therapeutics, Inc..

Intrinsic Value
Current Price: $7.23